ClinicalTrials.gg
Drug

Glofitamab clinical trials

Also written RO7082859 and Columvi.

studies test it
62
open now
42
in phase 3
4
first study started
2017

How each study uses glofitamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the glofitamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
15 Jun 2023 · COLUMVI · BLA 761309 (FDA, Drugs@FDA)
European Union
7 Jul 2023 · Columvi · EMEA/H/C/005751 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Glofitamab
55
Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859
8
Glofitamab-gxbm
5

Brand

Columvi
9
Columvi 10 mg
1

Development codes

RO7082859
20
RG6026
1

In one entry with another drug

Given together, or one or the other

Glofitamab + Obinutuzumab
2

Studies by the year they started

59 studies that test it; most in 2026 (19); 3 more planned to start later

Studies that test glofitamab, by start year
YearStudies
20171
20202
20214
20226
20237
20248
202512
202619

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
15
Phase 2
47
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 13 · Other 49

Hoffmann-La Roche (13) · National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (4) · Ruijin Hospital (3) · City of Hope Medical Center (3) · The Lymphoma Academic Research Organisation (2) · The First Affiliated Hospital with Nanjing Medical University (2) · The First Affiliated Hospital of Soochow University (2)

Often tested with

Tested in the same studies.

Obinutuzumab (8) · Lenalidomide (6) · Polatuzumab vedotin (6) · Gemcitabine (5) · Oxaliplatin (5) · Venetoclax (3) · Rituximab (3) · Mosunetuzumab (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 17, 2 in phase 3

Studies that test glofitamab, phase 3 first.

Studies

Open first, then newest update. How each study uses glofitamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 62

See all 62 studies that test glofitamab →

Given beside what is tested · 17 — glofitamab is usual care or a partner of the new treatment

Codes

What other systems call glofitamab · ClinicalTrials.gg INT001741

  • MeSH (NLM) C000720108glofitamabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 06P3KLK2J8GLOFITAMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q117846135glofitamabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C148486GlofitamabOne source FDA
  • DrugBank DB16371One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.